Atlas Trials

A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib

Clinical trial NCT01776723 · COMPLETED

Trial details

NCT number
NCT01776723
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Myelomonocytic Leukemia
Start date
2013-02-20
Primary completion
2018-11-28
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.